Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Related Clinical Trial
PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Official Title

A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy

Brief Summary

      This study aims to investigate the efficacy and safety of depemokimab compared with
      mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.

Study Phase

Phase 3

Study Type


Primary Outcome

Number of participants with remission (Birmingham Vasculitis Activity Score [BVAS] =0 and a dose of oral corticosteroid [OCS] less than or equal to [<=] 4 milligram [mg] per day)

Secondary Outcome

 Number of participants in each category of accrued duration of remission


Eosinophilic Granulomatosis With Polyangiitis



Study Arms / Comparison Groups

 Participants receiving depemokimab+placebo matching mepolizumab


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

July 14, 2022

Completion Date

November 7, 2025

Primary Completion Date

October 10, 2025

Eligibility Criteria

        Inclusion Criteria:

          -  Participant (male or female) must be 18 years of age or older at the time of signing
             the informed consent.

          -  Participants who are >=40 kilogram at Screening Visit 1.

          -  Participants with a documented diagnosis of EGPA for at least 6 months based on the
             history or presence of: asthma plus eosinophilia defined as >1.0*10^9/Liter (L) and/or
             >10 percentage (%) of leucocytes plus at least 2 of the following additional features
             of EGPA: a biopsy showing histopathological evidence of eosinophilic vasculitis, or
             perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation,
             neuropathy, mono or poly (motor deficit or nerve conduction abnormality), pulmonary
             infiltrates, non-fixed, sino-nasal abnormality, cardiomyopathy (established by
             echocardiography or magnetic resonance imaging), glomerulonephritis (hematuria, red
             cell casts, proteinuria), alveolar hemorrhage (by bronchoalveolar lavage), palpable
             purpura, anti-neutrophil cytoplasmic antibodies positive Myeloperoxidase or Proteinase

          -  History of relapsing OR refractory disease.

          -  Participants must be on a stable dose of oral prednisolone or prednisone of >=7.5
             mg/day (but not >50 mg/day) for at least 4 weeks prior to Baseline (Visit 2).

          -  If participants receiving immunosuppressive therapy (excluding cyclophosphamide) the
             dosage must be stable for the 4 weeks prior to Baseline (Visit 2) and during the

          -  A female participant is eligible to participate if she is not pregnant or
             breastfeeding, and one of the following conditions applies: Is a woman of
             non-childbearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP)
             and using a contraceptive method that is highly effective, with a failure rate of <1%.

          -  Capable of giving signed informed consent

        Exclusion Criteria:

          -  Participants diagnosed with granulomatosis with polyangiitis; previously known as
             Wegener's granulomatosis or microscopic polyangiitis.

          -  Participants with organ-threatening EGPA as per EULAR criteria,

          -  Imminently life-threatening EGPA disease within 3 months prior to Screening (Visit 1).

          -  A current malignancy or previous history of cancer in remission for less than 12
             months prior to Screening.

          -  Participants with alanine aminotransferase >2*upper limit of normal (ULN) or if
             participant is on background methotrexate or azathioprine >3*ULN, aspartate
             aminotransferase >2*ULN or if participant is on background methotrexate or
             azathioprine >3*ULN, alkaline phosphatase >=2.0*ULN, total bilirubin >1.5*ULN
             (isolated bilirubin >1.5*ULN is acceptable if bilirubin is fractionated and direct
             bilirubin <35%), Cirrhosis or current unstable liver or biliary disease per
             investigator assessment.

          -  Participants who have severe or clinically significant cardiovascular disease
             uncontrolled with standard treatment.

          -  Participants who have known, pre-existing, clinically significant system abnormalities
             that are not associated with EGPA and are uncontrolled with standard treatment.

          -  Clinically significant abnormality in the hematological, biochemical or urinalysis
             screen at Visit 1.

          -  Chronic or ongoing active infectious disease requiring systemic treatment.

          -  Participants with a known, pre-existing parasitic infestation within 6 months prior to
             Screening Visit 1.

          -  A known immunodeficiency (e.g. human immunodeficiency virus [HIV]).

          -  Participants that, according to the investigator's medical judgment, are likely to
             have active coronavirus disease 2019 (COVID-19) infection. Participants with known
             COVID-19 positive contacts within the past 14 days must be excluded for at least 14
             days following the exposure during which the participant must remain symptom-free.

          -  Participants with a known allergy or intolerance to a monoclonal antibody or biologic
             therapy or any of the excipients of the investigational products.

          -  Participants who have a previous documented failure with anti-Interleukin-5
             /Interleukin-5 receptor therapy. Participants who have received monoclonal antibodies
             (mAb) and who have not undergone the required washout periods, prior to Visit 1.

          -  Participants receiving any of the following: Oral corticosteroids: Participant
             requires an oral corticosteroid dose of >50 mg/day prednisolone/prednisone in the
             4-week period prior to Baseline (Visit 2), Intravenous (IV), intramuscular or
             subcutaneous (SC) corticosteroids in the 4-week period prior to Baseline (Visit 2),
             Omalizumab within 130 days prior to Screening (Visit 1), Cyclophosphamide (CYC): oral
             CYC within 4 weeks prior to Baseline (Visit 2) and IV CYC within 3 weeks prior to
             Baseline (Visit 2), if their total white blood cells is >=4*10^9/L (measured using the
             local laboratory if necessary), Rituximab within 12 months prior to Screening (Visit
             1); in addition, the Participant must have shown recovery of peripheral B-cell count
             to within the normal range, Tezepelumab and Dupilumab with a washout period of 5
             half-lives prior to Screening Visit 1, IV or SC immunoglobulin within 6 months prior
             to Screening (Visit 1); For China and Japan only within 12 weeks prior to Screening
             (Visit 1), Interferon-alpha within 6 months prior to Screening Visit 1, Anti-tumor
             necrosis factor therapy within 12 weeks prior to Screening Visit 1, Anti-CD52
             (alemtuzumab) within 6 months prior to Screening Visit 1.

          -  Participants with QT interval corrected for heart rate according to Fridericia's
             formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with
             Bundle Branch Block in the 12-lead ECG central over-read from at Screening Visit 1.




18 Years - N/A

Accepts Healthy Volunteers



GSK Clinical Trials, 877-379-3718, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor


Study Sponsor

GSK Clinical Trials, Study Director, GlaxoSmithKline

Verification Date

December 2022